Nyxoah SA
NYXH7.500USD
+0.200+2.74%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
280.70MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nyxoah SA Unternehmen
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Unternehmensinformationen
BörsenkürzelNYXH
Name des UnternehmensNyxoah SA
IPO-datumSep 18, 2020
CEOMr. Olivier Taelman
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeSep 18
AddresseRue Edouard Belin 12
StadtMONT-SAINT-GUIBERT
BörseEuronext Brussels
LandBelgium
Postleitzahl1435
Telefon3226121755
Websitehttps://www.nyxoah.com/
BörsenkürzelNYXH
IPO-datumSep 18, 2020
CEOMr. Olivier Taelman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.98M
+17.27%
Mr. John Landry
Mr. John Landry
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Loic Moreau
Mr. Loic Moreau
President - International
President - International
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Virginia Kirby
Ms. Virginia Kirby
Independent Director
Independent Director
--
--
Mr. Christoph Eigenmann
Mr. Christoph Eigenmann
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Rita F. Johnson-Mills
Ms. Rita F. Johnson-Mills
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pierre Gianello, M.D.
Dr. Pierre Gianello, M.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.98M
+17.27%
Mr. John Landry
Mr. John Landry
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Loic Moreau
Mr. Loic Moreau
President - International
President - International
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Virginia Kirby
Ms. Virginia Kirby
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, May 4
Aktualisiert: Sun, May 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cochlear Limited
15.05%
Taub (Robert)
10.62%
Monden (Anneliese)
7.86%
Gilde Healthcare Partners B.V.
7.85%
Vestal Point Capital, LP
4.84%
Other
53.79%
Aktionäre
Aktionäre
Anteil
Cochlear Limited
15.05%
Taub (Robert)
10.62%
Monden (Anneliese)
7.86%
Gilde Healthcare Partners B.V.
7.85%
Vestal Point Capital, LP
4.84%
Other
53.79%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
22.07%
Corporation
19.66%
Investment Advisor/Hedge Fund
9.78%
Venture Capital
7.85%
Investment Advisor
7.20%
Hedge Fund
0.53%
Research Firm
0.03%
Other
32.87%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
69
25.12M
67.13%
-3.04M
2025Q1
70
26.40M
70.53%
-2.65M
2024Q4
73
25.60M
68.47%
-1.01M
2024Q3
72
23.51M
71.46%
-828.78K
2024Q2
72
23.54M
72.39%
-1.11M
2024Q1
64
20.89M
72.68%
+374.51K
2023Q4
59
21.08M
73.36%
-418.05K
2023Q3
66
19.86M
69.10%
-2.56M
2023Q2
66
20.66M
78.20%
+1.01M
2023Q1
68
20.34M
78.50%
+892.06K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cochlear Limited
5.63M
15.05%
--
--
Dec 31, 2024
Taub (Robert)
3.98M
10.62%
+585.48K
+17.27%
Dec 31, 2024
Monden (Anneliese)
2.94M
7.86%
--
--
Dec 31, 2024
Gilde Healthcare Partners B.V.
2.94M
7.85%
--
--
Dec 31, 2024
Vestal Point Capital, LP
1.81M
4.84%
-509.11K
-21.95%
May 21, 2025
ResMed Inc
1.73M
4.62%
--
--
Dec 31, 2024
Hambrecht (Jürgen)
1.34M
3.59%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
1.11M
2.97%
-647.49K
-36.82%
Apr 29, 2025
BlackRock Financial Management, Inc.
965.58K
2.58%
-129.75K
-11.85%
Mar 31, 2025
BNP Paribas Asset Management Belgium S.A.
792.37K
2.12%
--
--
Aug 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Health Innovation Active ETF
0.12%
Avantis International Equity ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
SPDR Portfolio Europe ETF
0%
DFA Dimensional International Small Cap ETF
0%
Avantis International Small Cap Equity ETF
0%
iShares Health Innovation Active ETF
Anteil0.12%
Avantis International Equity ETF
Anteil0%
DFA Dimensional International Core Equity 2 ETF
Anteil0%
SPDR Portfolio Europe ETF
Anteil0%
DFA Dimensional International Small Cap ETF
Anteil0%
Avantis International Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
